Evaluation of prognostic parameters of E-cadherin status in breast cancer treatment

Annals of Agricultural and Environmental Medicine

Volumn 19, Issue 3, 2012, Pages 541-546

  Brzozowska, Anna ^a   Sodolski, Tomasz ^a   Duma, Dariusz ^a   Mazurkiewicz, Tomasz ^a   Mazurkiewicz, Maria ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Breast cancer; E cadherin; Prognosis

Indexed keywords

ANTIESTROGEN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; UVOMORULIN;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; CADHERINS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; POLAND; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84866689785     PISSN: 12321966     EISSN: 18982263     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Cowin P, Rowlands TM, Hatsell S J, et al. Cadherins and catenins in breast cancer. Curr Opin Cell Biol. 2005; 17: 499-508.
2. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251; 1451-1455.
3. Gumbinger B M. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996; 84, 345-357.
4. Brakebusch C, Bouvard D, Stanchi F. Integrins in invasive growth. J Clin Invest. 2002; 109: 999-1006.
5. Kowalski P J, Rubin M A, Kleer C G. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 2003; 5 (6): R217-R222.
6. Tang DG, Honn K V. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis. 1995; 14: 109-122.
7. Okegawa T, Pong RC, Li Y, et al. The role of cell adhesion molecule in cancer progression and its application in cancer theraphy. Acta Biochim Pol 2004; 51 (2): 445-457.
8. Ahmad IR, Hart IR. Mechanism of metastasis. Crit Rev Oncol Hematol 1997; 26 (3): 163-173.
9. Jeschke U, Mylonas I, Kuhn C. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence. Anticancer Res. 2007; 27 (4A): 1969-1974.
10. Larue L, Ohsugi M, Hirchenhain J, et al. E-cadherin nullmutant embryos fail to form a trophectoderm epithelium. Proc Natl Acad Sci U S A 1994; 91: 8263-8267.
11. Frixen UH, Behrens J, Sachs M, et al. E-cadherin mediatedcell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991; 113: 173-185.
12. Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994; 54: 3929-3933.
13. Umbas R, Isaacs WB, Bringuier PP, et al. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer.1997; 74: 374-377.
14. Mayer B, Johnson JP, Leitl F, et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 1993; 53: 1690-1695.
15. Dorudi S, Hanby AM, Poulsom R, et al. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer. 1995; 71: 614-616.
16. A Batistatou, D Peschos, H Tsanou, et al. In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin. Br J Cancer. 2007; 7;96 (9): 1404-1408.
17. Shiozaki H, Kobayashi K, et al. Expression of E-cadherincell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993; 53: 1696-1701.
18. Charpin C, Garcia S, Bonnier P, et al. Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival. Am J Clin Pathol. 1998; 109: 431-438.
19. Guriec N, Marcellin L, Gairard B, et al. E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survival. Invasion Metastasis. 1996; 16: 19-2.
20. Heimann R, Lan F, McBirde R, et al. Separating favorablefrom unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res. 2000; 60: 298-304.
21. Siitonen SM, Kononen JT, Helin HJ, et al. Reduced Ecadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol.1996; 105: 394-402.
22. De Leeuw WJ, Berx G, Vos CB, et al. Simultaneous loss of E-cadherinand catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 1997; 183: 404-411.
23. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol. 1993; 142: 987-993.
24. Moll R, Mitze M, Frixen UH, et al. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol. 1993; 143: 1731-1742.
25. Goldstein NS. Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemic metastasis? Am J Clin Pathol. 2002; 118: 425-434.
26. Lipponen P, Saarelainen E, Ji H, et al. Expression of E-cadherin as related to other prognostic factors and survival in breast cancer. J Pathol. 1994;174: 101-109.
27. Rimm DL, Sinard JH, Morrow JS. Reduced alpha-catenin and E-cadherin expression in breast cancer. Lab Invest. 1995; 72 (5): 506-512.
28. Parker C, Rampaul RS, Pinder SE, et al. E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer. 2001; 85 (12): 1958-1963.
29. Rubin MA, Mucci NR, Figurski J, et al. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol. 2001; 32: 690-697.
30. Suciu C, Cîmpean AM, Mureşan AM, et al. E-cadherin expression in invasive breast cancer. Rom J Morphol Embryol. 2008; 49 (4): 517-523.
31. Nikiel B, Chekan M, Jaworska M, et al. Expression of the selected adhesive molecules (cadherin E, CD44, LGAL3 and CA50) in papillary thyroid carcinoma. Pol J Endocrinol. 2006; 57 (4): 32-37.
32. Qureshi H, Linden M, Divine G, et al. E-cadherin Status in Breast Cancer Correlates With Histologic Type but Does Not Correlate With Established Prognostic Parameters. Am J Clin Pathol. 2006; 125 (3): 377-85.
33. Makdissi F, Machado L, Oliveira A. Expression of E-cadherin, Snail and Hakai in epithelial cells isolated from the primary tumor and from peritumoral tissue of invasive ductal breast carcinomas. Braz J Med Biol Res. 2009; 42 (12): 1128-1137.
34. Rakha EA, Abd El Rehim D, Pinder SE. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 2005; 46 (6): 685-93.
35. Guriec N, Marcellin L, Gairard B, et al. E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survival. Invasion Metastasis 1996; 16: 19-26.
36. Berezhnaya N, Belova O, Vinnichuk Y, et al. Expression of e-cadherin in drug resistant human breast cancer cells and their sensitivity to lymphokine-activated lymphocytes action Exp Oncol. 2009; 31 (4): 242-245.
37. Heimann R, Lan F, McBride R, Hellman S. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res. 2000; 60 (2): 298-304.
38. Bukholm IR, Nesland JM, Bukholm G. Expression of adhesion proteins E-cadherin, alpha-catenin, beta-catenin and gamma-catenin is different in T1 and T2 breast tumours. Pathology 2006; 38 (5): 403-7.
39. Da Silva BB, dos Santos Ar, Pires CG. E-cadherin expression in estrogen receptor-positive and negative breast carcinomas of postmenopausal women. Eur J Gynaecol Oncol. 2010; 31 (1): 90-3.
40. Mohammadizadeh F, Ghasemibasir H, Rajabi P. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma. Cancer Biomark. 2009; 5 (1): 1-8.